antidepressants - Page 1 | CARLAT PUBLISHING

Expert Q&A

Perinatal Mental Health

January 28, 2026

Amritha Bhat, MBBS, MD, MPH. Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Washington.

Dr. Bhat has no financial relationships with companies related to this material.

We take a close look at the new FDA panel on antidepressants in pregnancy, treatment guidelines for postpartum psychosis, and the role of zuranolone.

Research Update

Vitamin D Has Dose-Dependent Effect on Depressive Symptoms

January 28, 2026

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Investigators reveal measurable antidepressant effects of Vitamin D but limited benefits for anxiety, quality of life, or depression remission.

Research Update

Comparing Options for Treatment-Resistant Depression

September 1, 2025

Dominic Le, MD

Dominic Le, MD. Dr. Le has no financial relationships with companies related to this material.

Two new and related studies compare treatments for resistant depression, shedding light on how different strategies stack up after medication trials fail.

You’re sitting with a patient. They’re worried about weight gain.

August 1, 2025

Daniel Carlat, MD

You’re sitting with a patient.

They’ve had terrible luck with sexual side effects.
And you’re silently trying to recall which SSRI is "less bad" on GI issues.
It’s not that you don’t know the data—it’s that it’s never all in one place.

Weight Changes and Antidepressants: What to Tell Patients

May 1, 2025

Dominic Le, MD

Dominic Le, MD. Dr. Le has no financial relationships with companies related to this material.

When patients ask about weight changes with antidepressants, providing guidance can be challenging. While bupropion is often considered weight-neutral and paroxetine an offender, how do other common antidepressants compare?

Benzodiazepines

May 1, 2025

Daniel Morehead MD

Director, General Psychiatry Residency Program, Tufts Medical Center.

Dr. Morehead has no financial relationships with companies related to this material.

Dr. Morehead discusses when to use them, how to taper them, and new research on withdrawal risks.

Enhancing Antidepressant Efficacy in Older Adults

April 1, 2025

Jaime A.B. Wilson, PhD, ABN

Jaime A.B. Wilson, PhD, ABN. Dr. Wilson has no financial relationships with companies related to this material.

It’s not just finding the antidepressant—dose, duration, and augmentation strategies matter.

Clinical Update

Gepirone: A First Look

September 3, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Learn about the risks and efficacy of gepirone (Exxua) for treating MDD.

Expert Q&A

Treatment Challenges in Atypical Parkinsonism

July 1, 2024

Alice Flaherty, MD, PhD

Alice Flaherty, MD, PhD.

Neurologist, Massachusetts General Hospital; associate professor of neurology and psychiatry, Harvard Medical School, Cambridge, MA.

Dr. Flaherty has no financial relationships with companies related to this material.

Patients with atypical parkinsonism are less responsive to levodopa, and psychiatric medications can exacerbate motor symptoms. Dr. Flaherty advises how to choose the right treatment in patients with parkinsonism accompanied by psychosis, apathy, anxiety, and depression.

Risks in Older Adults

Antidepressants and Hyponatremia

April 1, 2024

Heather Robles, PharmD and Talia Puzantian, PharmD, BCPP

Heather Robles, PharmD candidate, and Talia Puzantian, PharmD, BCPP. Ms. Robles and Dr. Puzantian have no financial relationships with companies related to this material.

A brief review of hyponatremia including medications that cause it, symptoms to look out for, and how to prevent and treat this common side effect.